Isoliquiritin apioside |
| Catalog No.GC39095 |
L'apioside d'isoliquiritine diminue de manière significative les augmentations induites par le PMA des activités de MMP9 et supprime l'activation induite par le PMA de MAPK et de NF-κB. L'apioside d'isoliquiritine supprime le caractère invasif et l'angiogenèse des cellules cancéreuses et des cellules endothéliales.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 120926-46-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Isoliquiritin apioside, a component isolated from Glycyrrhizae radix rhizome, significantly decreases PMA-induced increases in MMP9 activities and suppresses PMA-induced activation of MAPK and NF-κB. Isoliquiritin apioside auppresseses invasiveness and angiogenesis of cancer cells and endothelial cells[1].
[1]. Kim A1, et al. Isoliquiritin Apioside Suppresses in vitro Invasiveness and Angiogenesis of Cancer Cells and Endothelial Cells.Front Pharmacol. 2018 Dec 10;9:1455.
Average Rating: 5 (Based on Reviews and 38 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *